Exercise or conversion
Melissa B. Epperly
Director
Common Shares
- Value context
- $79.17K
- Reported price
- $4.46 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Roivant Sciences Ltd.
Last 30 daysNo qualifying insider buying. Sales: $9.16M by 3 insiders.
Showing the first 6 of 137 trades on this page.
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CEO
Common Shares
President and Vant Chair
Common Shares
President & CIO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chief Accounting Officer
Common Shares
CFO
Common Shares
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CFO
Common Shares
President & Immunovant CEO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Common Shares
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Common Shares
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
CEO
Common Shares
Director
Common Shares
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President and Vant Chair
Common Shares
President & CIO
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Other reporting owner
Common Shares
Other reporting owner
Common Shares
Other reporting owner
Common Shares
Other reporting owner
Common Shares
Other reporting owner
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CFO
Common Shares
Chief Accounting Officer
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CFO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CFO
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
CFO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Accounting Officer
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Accounting Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
CEO
Common Shares
Chief Accounting Officer
Common Shares
President and Vant Chair
Common Shares
CEO
Common Shares
CEO
Common Shares
CEO
Common Shares
CEO
Capped Value Appreciation Rights
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Capped Value Appreciation Rights
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Common Shares
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesOption exercise or conversion10b5-1 | 17,750$4.46 / share | $79.17K | Oct 1Filed Oct 5 · 4d later | SEC filing |
| Director | Common SharesSale10b5-12 trades | 17,750avg $36.10 / share | $640.86K | Oct 1Filed Oct 5 · 4d later | 2 filings
|
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units17,750$4.46 exercise / conversion price | Not a separate purchase | Oct 1Filed Oct 5 · 4d later | SEC filing |
| CEO | Common SharesExercise-price or tax withholding | 76,171$36.57 / share | $2.79M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President and Vant Chair | Common SharesExercise-price or tax withholding | 40,309$36.57 / share | $1.47M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & CIO | Common SharesExercise-price or tax withholding | 46,879$36.57 / share | $1.71M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$36.62 / share | $7.32M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Sep 30Filed Oct 2 · 2d later | SEC filing |
| Chief Accounting Officer | Common SharesExercise-price or tax withholding | 3,880$39.77 / share | $154.31K | Sep 20Filed Sep 22 · 2d later | SEC filing |
| CFO | Common SharesExercise-price or tax withholding | 2,129$39.77 / share | $84.67K | Sep 20Filed Sep 22 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesSale10b5-12 trades | 4,938avg $39.74 / share | $196.23K | Sep 15Filed Sep 17 · 2d later | 2 filings
|
| Director | Common SharesSale10b5-12 trades | 5,112avg $39.74 / share | $203.15K | Sep 15Filed Sep 17 · 2d later | 2 filings
|
| Director | Common SharesExercise-price or tax withholding | 5,133$40.94 / share | $210.15K | Sep 10Filed Sep 14 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 2,378$40.94 / share | $97.36K | Sep 10Filed Sep 14 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 2,179$40.94 / share | $89.21K | Sep 10Filed Sep 14 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 1,743$40.94 / share | $71.36K | Sep 10Filed Sep 14 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 2,905$40.94 / share | $118.93K | Sep 10Filed Sep 14 · 4d later | SEC filing |
| Director | Common SharesOption exercise or conversion10b5-1 | 20,000$8.80 / share | $176K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Director | Common SharesSale10b5-1 | 20,000$39.90 / share | $798K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units20,000$8.80 exercise / conversion price | Not a separate purchase | Sep 8Filed Sep 10 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Aug 28Filed Sep 1 · 4d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-12 trades | 200,000avg $35.77 / share | $7.15M | Aug 28Filed Sep 1 · 4d later | 2 filings
|
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Aug 28Filed Sep 1 · 4d later | SEC filing |
| CFO | Common SharesExercise-price or tax withholding | 5,749$36.84 / share | $211.79K | Aug 20Filed Aug 24 · 4d later | SEC filing |
| President & Immunovant CEO | Common SharesExercise-price or tax withholding | 13,909$36.84 / share | $512.41K | Aug 20Filed Aug 24 · 4d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 172,899$3.85 / share | $665.66K | Aug 19Filed Aug 21 · 2d later | SEC filing |
| President & CIO | Common SharesSale | 172,899$37.17 / share | $6.43M | Aug 19Filed Aug 21 · 2d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 17,519$3.85 / share | $67.45K | Aug 20Filed Aug 21 · 1d later | SEC filing |
| President & CIO | Common SharesSale | 17,519$37.30 / share | $653.46K | Aug 20Filed Aug 21 · 1d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 144,756$3.85 / share | $557.31K | Aug 21Filed Aug 21 · 0d later | SEC filing |
| President & CIO | Common SharesSale | 144,756$36.48 / share | $5.28M | Aug 21Filed Aug 21 · 0d later | SEC filing |
| President & CIO | Stock Option (Right to Buy)Option exercise or conversion | Derivative units172,899$3.85 exercise / conversion price | Not a separate purchase | Aug 19Filed Aug 21 · 2d later | SEC filing |
| President & CIO | Stock Option (Right to Buy)Option exercise or conversion | Derivative units17,519$3.85 exercise / conversion price | Not a separate purchase | Aug 20Filed Aug 21 · 1d later | SEC filing |
| President & CIO | Stock Option (Right to Buy)Option exercise or conversion | Derivative units144,756$3.85 exercise / conversion price | Not a separate purchase | Aug 21Filed Aug 21 · 0d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 243,177$3.85 / share | $936.23K | Aug 14Filed Aug 18 · 4d later | SEC filing |
| President & CIO | Common SharesSale | 243,177$36.23 / share | $8.81M | Aug 14Filed Aug 18 · 4d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 284,707$3.85 / share | $1.1M | Aug 17Filed Aug 18 · 1d later | SEC filing |
| President & CIO | Common SharesSale | 284,707$36.25 / share | $10.32M | Aug 17Filed Aug 18 · 1d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 105,141$3.85 / share | $404.79K | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CIO | Common SharesSale | 105,141$36.59 / share | $3.85M | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 31,801$3.85 / share | $122.43K | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CIO | Common SharesSale | 31,801$37.18 / share | $1.18M | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | Derivative units243,177$3.85 exercise / conversion price | Not a separate purchase | Aug 14Filed Aug 18 · 4d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | Derivative units284,707$3.85 exercise / conversion price | Not a separate purchase | Aug 17Filed Aug 18 · 1d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | Derivative units136,942$3.85 exercise / conversion price | Not a separate purchase | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Jul 27Filed Jul 29 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$34.95 / share | $6.99M | Jul 27Filed Jul 29 · 2d later | SEC filing |
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Jul 27Filed Jul 29 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 405Award · no purchase price | Non-cash award | Jul 17Filed Jul 21 · 4d later | SEC filing |
| Director | Common SharesGrant or award | 543Award · no purchase price | Non-cash award | Jul 17Filed Jul 21 · 4d later | SEC filing |
| Director | Common SharesGrant or award | 775Award · no purchase price | Non-cash award | Jul 17Filed Jul 21 · 4d later | SEC filing |
| CEO | Common SharesExercise-price or tax withholding | 76,171$35.39 / share | $2.7M | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Director | Common SharesOption exercise or conversion10b5-1 | 10,000$8.80 / share | $88K | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Director | Common SharesSale10b5-1 | 10,000$34.90 / share | $349K | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units10,000$8.80 exercise / conversion price | Not a separate purchase | Jun 30Filed Jul 2 · 2d later | SEC filing |
| President and Vant Chair | Common SharesExercise-price or tax withholding | 40,310$35.39 / share | $1.43M | Jun 30Filed Jul 2 · 2d later | SEC filing |
| President & CIO | Common SharesExercise-price or tax withholding | 46,878$35.39 / share | $1.66M | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Director | Common SharesOption exercise or conversion10b5-1 | 17,750$4.46 / share | $79.17K | Jun 29Filed Jul 1 · 2d later | SEC filing |
| Director | Common SharesSale10b5-12 trades | 17,750avg $34.38 / share | $610.25K | Jun 29Filed Jul 1 · 2d later | 2 filings
|
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units17,750$4.46 exercise / conversion price | Not a separate purchase | Jun 29Filed Jul 1 · 2d later | SEC filing |
| Director | Common SharesSale2 trades | 625,783avg $34.00 / share | $21.28M | Jun 26Filed Jun 30 · 4d later | 2 filings
|
| Director | Common SharesSale2 trades | 800,000avg $34.55 / share | $27.64M | Jun 29Filed Jun 30 · 1d later | 2 filings
|
| Director | Common SharesSale2 trades | 212,380avg $35.44 / share | $7.53M | Jun 30Filed Jun 30 · 0d later | 2 filings
|
| Director | Common SharesSale2 trades | 625,783avg $34.00 / share | $21.28M | Jun 26Filed Jun 30 · 4d later | 2 filings
|
| Director | Common SharesSale2 trades | 800,000avg $34.55 / share | $27.64M | Jun 29Filed Jun 30 · 1d later | 2 filings
|
| Director | Common SharesSale | 12,380$35.28 / share | $436.77K | Jun 30Filed Jun 30 · 0d later | SEC filing |
| Other reporting owner | Common SharesSale2 trades | 625,783avg $34.00 / share | $21.28M | Jun 26Filed Jun 30 · 4d later | 2 filings
|
| Other reporting owner | Common SharesSale2 trades | 800,000avg $34.55 / share | $27.64M | Jun 29Filed Jun 30 · 1d later | 2 filings
|
| Other reporting owner | Common SharesSale | 12,380$35.28 / share | $436.77K | Jun 30Filed Jun 30 · 0d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 500,000$3.85 / share | $1.93M | Jun 25Filed Jun 29 · 4d later | SEC filing |
| President & CIO | Common SharesSale | 500,000$34.13 / share | $17.07M | Jun 25Filed Jun 29 · 4d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 500,000$3.85 / share | $1.93M | Jun 26Filed Jun 29 · 3d later | SEC filing |
| President & CIO | Common SharesSale | 500,000$34.08 / share | $17.04M | Jun 26Filed Jun 29 · 3d later | SEC filing |
| President & CIO | Stock Option (Right to Buy)Option exercise or conversion | Derivative units500,000$3.85 exercise / conversion price | Not a separate purchase | Jun 25Filed Jun 29 · 4d later | SEC filing |
| President & CIO | Stock Option (Right to Buy)Option exercise or conversion | Derivative units500,000$3.85 exercise / conversion price | Not a separate purchase | Jun 26Filed Jun 29 · 3d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Jun 24Filed Jun 26 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-12 trades | 200,000avg $33.16 / share | $6.63M | Jun 24Filed Jun 26 · 2d later | 2 filings
|
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Jun 24Filed Jun 26 · 2d later | SEC filing |
| CFO | Common SharesExercise-price or tax withholding | 2,129$31.43 / share | $66.91K | Jun 20Filed Jun 23 · 3d later | SEC filing |
| Chief Accounting Officer | Common SharesExercise-price or tax withholding | 3,582$31.43 / share | $112.58K | Jun 20Filed Jun 23 · 3d later | SEC filing |
| President & Immunovant CEO | Common SharesExercise-price or tax withholding10b5-1 | 34,483$32.41 / share | $1.12M | May 20Filed May 22 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | May 22Filed May 22 · 0d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$30.27 / share | $6.05M | May 22Filed May 22 · 0d later | SEC filing |
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | May 22Filed May 22 · 0d later | SEC filing |
| CFO | Common SharesExercise-price or tax withholding | 18,962$32.41 / share | $614.56K | May 20Filed May 22 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Apr 20Filed Apr 22 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$29.59 / share | $5.92M | Apr 20Filed Apr 22 · 2d later | SEC filing |
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Apr 20Filed Apr 22 · 2d later | SEC filing |
| CFO | Common SharesGrant or award | 60,644Award · no purchase price | Non-cash award | Apr 20Filed Apr 22 · 2d later | SEC filing |
| CFO | Stock Option (Right to Buy)Grant or award | Derivative units84,026Award · no purchase price | Non-cash award | Apr 20Filed Apr 22 · 2d later | SEC filing |
| Chief Accounting Officer | Common SharesGrant or award | 29,173Award · no purchase price | Non-cash award | Apr 20Filed Apr 22 · 2d later | SEC filing |
| Chief Accounting Officer | Stock Option (Right to Buy)Grant or award | Derivative units27,157Award · no purchase price | Non-cash award | Apr 20Filed Apr 22 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 896Award · no purchase price | Non-cash award | Apr 17Filed Apr 21 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 95$29.83 / share | $2.83K | Apr 17Filed Apr 21 · 4d later | SEC filing |
| Director | Common SharesGrant or award | 670Award · no purchase price | Non-cash award | Apr 17Filed Apr 21 · 4d later | SEC filing |
| Director | Common SharesGrant or award | 469Award · no purchase price | Non-cash award | Apr 17Filed Apr 21 · 4d later | SEC filing |
| Director | Common SharesExercise-price or tax withholding | 94$29.83 / share | $2.8K | Apr 17Filed Apr 21 · 4d later | SEC filing |
| CEO | Common SharesSale | 289,774$29.16 / share | $8.45M | Apr 16Filed Apr 20 · 4d later | SEC filing |
| Chief Accounting Officer | Common SharesSale | 13,538$28.37 / share | $384.07K | Apr 8Filed Apr 10 · 2d later | SEC filing |
| President and Vant Chair | Common SharesExercise-price or tax withholding | 160,035$27.70 / share | $4.43M | Mar 31Filed Apr 2 · 2d later | SEC filing |
| CEO | Common SharesOption exercise or conversion | 97,319Price not reported | Unavailable | Mar 30Filed Apr 1 · 2d later | SEC filing |
| CEO | Common SharesExercise-price or tax withholding | 53,826$26.41 / share | $1.42M | Mar 30Filed Apr 1 · 2d later | SEC filing |
| CEO | Common SharesExercise-price or tax withholding | 304,684$27.70 / share | $8.44M | Mar 31Filed Apr 1 · 1d later | SEC filing |
| CEO | Capped Value Appreciation RightsOption exercise or conversion | Derivative units2,178,150Exercise / conversion price not reported | Not a separate purchase | Mar 30Filed Apr 1 · 2d later | SEC filing |
| President & CIO | Common SharesOption exercise or conversion | 58,391Price not reported | Unavailable | Mar 30Filed Apr 1 · 2d later | SEC filing |
| President & CIO | Common SharesExercise-price or tax withholding | 29,809$26.41 / share | $787.26K | Mar 30Filed Apr 1 · 2d later | SEC filing |
| President & CIO | Common SharesExercise-price or tax withholding | 187,512$27.70 / share | $5.19M | Mar 31Filed Apr 1 · 1d later | SEC filing |
| President & CIO | Capped Value Appreciation RightsOption exercise or conversion | Derivative units1,306,889Exercise / conversion price not reported | Not a separate purchase | Mar 30Filed Apr 1 · 2d later | SEC filing |
| Director | Common SharesOption exercise or conversion | 70,000$8.80 / share | $616K | Mar 26Filed Mar 30 · 4d later | SEC filing |
| Director | Common SharesSale | 70,000$27.45 / share | $1.92M | Mar 26Filed Mar 30 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Option exercise or conversion | Derivative units70,000$8.80 exercise / conversion price | Not a separate purchase | Mar 26Filed Mar 30 · 4d later | SEC filing |
Roivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a purchase for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.